News Theranexus

Equities

ALTHX

FR0013286259

Real-time Euronext Paris Other stock markets 10:08:55 2024-04-25 am EDT			5-day change	1st Jan Change
1.12 ^EUR	0.00%		+6.16%	0.00%

Apr. 19	Theranexus: share price rises following promising trial results	CF
Mar. 11	Theranexus: CEO takes over as Chairman of the Board	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theranexus : Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide	Apr. 23	AT
Theranexus: share price rises following promising trial results	Apr. 19	CF
Theranexus : Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1	Apr. 18	AT
Theranexus: CEO takes over as Chairman of the Board	Mar. 11	CF
Theranexus : THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN	Mar. 11	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS	Feb. 14	AT
Certain Ordinary Shares of Theranexus Société Anonyme are subject to a Lock-Up Agreement Ending on 11-JAN-2024.	Jan. 10	CI
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023	23-10-17	AT
Theranexus: promising results in Batten disease	23-09-29	CF
Theranexus : Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1	23-09-29	AT
Theranexus : THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS	23-09-28	AT
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Theranexus : Theranexus raises around 3.1 million euros in fundraising	23-07-12	AT
Theranexus SociÃ©tÃ© Anonyme announced that it has received â‚¬2.470412 million in funding	23-07-11	CI
Theranexus: share price rises on promising trials	23-06-14	CF
Theranexus : Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)	23-06-14	AT
Theranexus: EMA positive on Phase 3 design	23-06-07	CF
Global markets live: Lucid, Under Armour, Coty, PayPal, Western Digital...	23-05-09
Erytech: renewed confidence in merger project	23-05-09	CF
Theranexus: FDA approval for Batten disease	23-05-09	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Theranexus

Equities

ALTHX

FR0013286259

Summary

Filters